These observations suggest that EHF may be a new transcription factor for HER2 and HER3 in thyroid cancer by binding to a functional EBS within their promoter, and plays its oncogenic function by activating HER family of receptor tyrosine kinases, contributing to thyroid tumorigenesis. Here, NTRK1 is linked to thyroid cancer.